Skip to main
INFU

InfuSystem Hlds (INFU) Stock Forecast & Price Target

InfuSystem Hlds (INFU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

InfuSystems Holdings Inc. reported a robust financial performance with a significant year-over-year increase in gross profit, expanding by $2.2 million to reach $20.4 million while gross margin grew 260 basis points to 56.4%. The company's core oncology business achieved record quarterly revenue, further supported by a new contract with a large hospital system, which is anticipated to enhance patient volumes in the upcoming quarters. Additionally, net operating cash flow improved markedly to $17.3 million, reflecting a 38% increase due to higher earnings and improved working capital management, underscoring the company’s financial strength and operational efficiency.

Bears say

InfuSystems Holdings faces a significant reduction in anticipated annual revenue of $7.1 million in 2026 due to a restructured contract with its largest biomedical services customer, adding pressure to its financial outlook. Additionally, the company is experiencing margin compression and competitive challenges, alongside reduced sales rep productivity, which collectively hinder the potential for revenue growth. Cash flow from operations showed a decline of 10% year-over-year in Q4 2025, raising concerns about the sustainability of operational performance in the long term.

InfuSystem Hlds (INFU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InfuSystem Hlds (INFU) Forecast

Analysts have given InfuSystem Hlds (INFU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, InfuSystem Hlds (INFU) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InfuSystem Hlds (INFU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.